SCHEMBL964915

SCHEMBL964915

CC(C)CCOC(=O)Nc1cccnc1

nearest known ligand 0.59

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 2/20 0.54
RAB9A P51151 8/20 0.50
SORT1 Q99523 1/20 0.50
HTT P42858 1/20 0.50
NPC1 O15118 6/20 0.49
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
ALDH1A1 P00352 2/20 0.48
EPHX2 P34913 1/20 0.48
PKM P14618 3/20 0.48
FPR2 P25090 1/20 0.47
NOTUM Q6P988 1/20 0.47
NAMPT P43490 1/20 0.47
MAPT P10636 1/20 0.47
TP53 P04637 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL964959 0.92 CHRNA7 (0.58) CHRNA7RAB9ASORT1HTTNPC1
SCHEMBL967303 0.91 CHRNA7 (0.57) CHRNA7RAB9ASORT1HTTNPC1
SCHEMBL965249 0.90 CHRNA7 (0.56) CHRNA7RAB9ASORT1HTTNPC1
SCHEMBL963949 0.86 ALDH1A1 (0.53) CHRNA7RAB9AHTTNPC1MEN1
SCHEMBL30352411 0.86 ALDH1A1 (0.53) CHRNA7RAB9AHTTNPC1MEN1
SCHEMBL965412 0.84 NPC1 (0.60) CHRNA7RAB9ANPC1MEN1KMT2A
SCHEMBL5540368 0.82 LMNA (0.62) RAB9ANPC1MEN1KMT2AALDH1A1
SCHEMBL964143 0.82 CHRNA7 (0.62) CHRNA7RAB9ANPC1MEN1KMT2A
SCHEMBL966665 0.81 NPC1 (0.59) CHRNA7RAB9AHTTNPC1ALDH1A1
SCHEMBL30058651 0.81 NPC1 (0.59) CHRNA7RAB9AHTTNPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2471775-A1 Manufacturing method for a piperidine-3-ylcarbamate compound and optical resolution method therefor SUMITOMO CHEMICAL CO., LTD. (JP) 2012-07-04 EP disclosed
CN-101977899-A Manufacturing method for a piperidine-3-ylcarbamate compound and optical resolution method therefor SUMITOMO CHEMICAL CO 2011-02-16 CN disclosed
US-20110021780-A1 MANUFACTURING METHOD FOR A PIPERIDINE-3-YLCARBAMATE COMPOUND AND OPTICAL RESOLUTION METHOD THEREFOR SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-01-27 US disclosed
EP-2269986-A1 MANUFACTURING METHOD FOR A PIPERIDINE-3-YLCARBAMATE COMPOUND AND OPTICAL RESOLUTION METHOD THEREFOR Sumitomo Chemical Company, Limited (JP) 2011-01-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110021780-A1 MANUFACTURING METHOD FOR A PIPERIDINE-3-YLCARBAMATE COMPOUND AND OPTICAL RESOLUTION METHOD THEREFOR PDCD2L, NOTUM, OXA1L CHRNA7 2474/4885RAB9A 2197/4885SORT1 4102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.